Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12862879 | 0.88 | HTT (0.45) | KMT2AMEN1MAPTHTTPKM | |
| SCHEMBL12862887 | 0.79 | PNMT (0.45) | KMT2AMEN1MAPTALDH1A1POLB | |
| SCHEMBL1168454 | 0.78 | HTT (0.46) | KMT2AMEN1MAPTHTTPKM | |
| SCHEMBL1167587 | 0.77 | CHRNB4 (0.42) | KMT2AMEN1MAPTHTTPKM | |
| SCHEMBL31444563 | 0.77 | KMT2A (0.64) | KMT2AMEN1MAPTALDH1A1MAPK1 | |
| SCHEMBL14468050 | 0.77 | ALDH1A1 (0.43) | KMT2AMAPTHTTALDH1A1POLB | |
| SCHEMBL16104865 | 0.76 | ADRA2A (0.46) | KMT2AMEN1MAPTHTTPKM | |
| SCHEMBL12862897 | 0.76 | LOXL2 (0.41) | KMT2AMEN1ALDH1A1AKR1B1 | |
| SCHEMBL1168091 | 0.75 | ADRA2A (0.42) | ALDH1A1SMN1; SMN2AKR1B1MAPK1 | |
| SCHEMBL14468102 | 0.75 | CHRNB4 (0.39) | KMT2AMEN1MAPTHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070167469-A1 | Pyrido-pyrimidine derivatives, preparation thereof, and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167469-A1 | Pyrido-pyrimidine derivatives, preparation thereof, and therapeutic use thereof | DPYD, PNPO, TYMP | KMT2A 3836/4885MEN1 3901/4885MAPT 2111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.